NCT06643884 Suprachoroidal Administration in Subjects With Metastases to the Choroid
| NCT ID | NCT06643884 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Aura Biosciences |
| Condition | Eye Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2026-11-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Eligibility Criteria
Inclusion Criteria: * Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor. * Have at least one Metastases to the Choroid in the study eye Exclusion Criteria: * Active ocular infection or disease. * Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment. * Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.